Patents by Inventor Steingrimor P. Stefansson

Steingrimor P. Stefansson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Mutant plasminogen activator-inhibitor type 1 (PAI-1) and uses thereof
    Patent number: 7388074
    Abstract: Mutants of the human PAI-1 protein are described which are inhibitors of neutrophil elastase or are inhibitors of vitronectin (Vn)-dependent cell migration. These mutants preferably comprise one or two amino acid substitutions in the reactive center loop of PAI-1, particularly at positions 331 and 346 of the mature protein. These mutants are notable in being resistant to inactivation by elastase, having high affinity for Vn, or both properties. These mutant proteins as pharmaceutical compositions are used to inhibit elastase in a subject, thereby treating a number of disorders associated with elastase activity, most notatably emphysema, ARDS, inflammatory lung injury and cystic fibrosis. The mutants which interact with Vn are used to inhibit cell migration in a subject, thereby treating diseases or conditions associated with undesired cell migration and proliferation, particularly of smooth muscle cells.
    Type: Grant
    Filed: September 30, 2002
    Date of Patent: June 17, 2008
    Assignee: The Regents of The University of Michigan
    Inventors: Daniel A. Lawrence, Steingrimor P. Stefansson
  • Mutant plasminogen activator-inhibitor type 1 (PAI-1) and uses thereof
    Publication number: 20030216321
    Abstract: Mutants of the human PAI-1 protein are described which are inhibitors of neutrophil elastase or are inhibitors of vitronectin (Vn)-dependent cell migration. These mutants preferably comprise one or two amino acid substitutions in the reactive center loop of PAI-1, particularly at positions 331 and 346 of the mature protein. These mutants are notable in being resistant to inactivation by elastase, having high affinity for Vn, or both properties. These mutant proteins as pharmaceutical compositions are used to inhibit elastase in a subject, thereby treating a number of disorders associated with elastase activity, most notatably emphysema, ARDS, inflammatory lung injury and cystic fibrosis. The mutants which interact with Vn are used to inhibit cell migration in a subject, thereby treating diseases or conditions associated with undesired cell migration and proliferation, particularly of smooth muscle cells.
    Type: Application
    Filed: September 30, 2002
    Publication date: November 20, 2003
    Applicant: American Red Cross
    Inventors: Daniel A. Lawrence, Steingrimor P. Stefansson